Human sVEGFR3/Flt-4 DuoSet ELISA | R&D Systems DY349B-05 product information

product summary

company name :

R&D Systems

product type :

ELISA/assay

product name :

Human sVEGFR3/Flt-4 DuoSet ELISA

catalog :

DY349B-05

quantity :

1 Kit (for 5 Plates)

price :

440 USD

more info or order :

R&D Systems product webpage

citations: 10

Reference
Kumar N, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, et al. Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J Infect. 2017;74:10-21 pubmed publisher
Kumar N, Banurekha V, Nair D, Babu S. Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE. 2016;11:e0146318 pubmed publisher
Tabata T, Petitt M, Fang Hoover J, Rivera J, Nozawa N, Shiboski S, et al. Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation model. Am J Pathol. 2012;181:1540-59 pubmed publisher
Llovet J, Peña C, Lathia C, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290-300 pubmed publisher
Harmon C, DePrimo S, Raymond E, Cheng A, Boucher E, Douillard J, et al. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med. 2011;9:120 pubmed publisher
Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, et al. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther. 2009;17:278-84 pubmed publisher
Rini B, Michaelson M, Rosenberg J, Bukowski R, Sosman J, Stadler W, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3743-8 pubmed publisher
Burstein H, Elias A, Rugo H, Cobleigh M, Wolff A, Eisenberg P, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810-6 pubmed publisher
Lee J, Cho E, Namkung J, Kim E, Kim S, Shin E, et al. Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in Koreans. J Invest Dermatol. 2008;128:1599-603 pubmed
Saltz L, Rosen L, Marshall J, Belt R, Hurwitz H, Eckhardt S, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25:4793-9 pubmed

image

image 1 :

Human VEGF R3/ Flt-4 ELISA Standard Curve

product information

master code :

DY349B-05

SKU :

DY349B-05

product name :

Human sVEGFR3/Flt-4 DuoSet ELISA

unit size :

1 Kit (for 5 Plates)

description :

The Human sVEGFR3/Flt-4 DuoSet ELISA from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human VEGFR3/Flt-4.

target :

VEGFR3/Flt-4

category :

ELISAs

species :

Human

kit type :

Solid Phase Sandwich ELISA

elisaRange :

93.80 - 6000 pg/mL

top caption :

Human VEGF R3/ Flt-4 ELISA Standard Curve

applications :

ELISA

USD :

440 USD

alt names :

EC 2.7.10, EC 2.7.10.1, Flt-4, FLT4, fms-related tyrosine kinase 4, LMPH1A, PCLFLT41, soluble VEGFR3 variant 1, soluble VEGFR3 variant 2, soluble VEGFR3 variant 3, Tyrosine-protein kinase receptor FLT4, vascular endothelial growth factor receptor 3, VEGF R3, VEGFR-3, VEGFR3Fms-like tyrosine kinase 4

storage :

Store the unopened product at 2 - 8 ░C. Do not use past expiration date.

more info or order :

R&D Systems product webpage